Wilson, Sonsini, Goodrich & Rosati advised Opiant Pharmaceuticals, while Kramer Levin advised Pontifax on the deal. Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
